Medicare Enrolled
Dr. Dina Tebcherany, MD
Medical Oncology · Austin, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Tebcherany from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tebcherany? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tebcherany
Dr. Dina Tebcherany is a medical oncology in Austin, TX, with 19 years in practice. Based on federal Medicare data, Dr. Tebcherany performed 159,618 Medicare services across 4,036 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tebcherany received a total of $304 from 10 pharmaceutical and/or device companies across 14 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tebcherany is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 4% volume in TX$ $304 industry payments
Medicare Practice Summary
Medicare Utilization ↗159,618
Medicare services
Top 4% in TX for medical oncology
4,036
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~8,401 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 26,200 | $43 | $137 |
| Iron sucrose injection (Venofer) | 20,200 | $0 | $2 |
| Paclitaxel chemotherapy injection | 17,310 | $0 | $8 |
| Oxaliplatin chemotherapy injection | 15,700 | $0 | $33 |
| Iron infusion (Feraheme) | 14,790 | $0 | $5 |
| Nivolumab injection (Opdivo) | 12,960 | $24 | $76 |
| Anti-nausea injection (fosaprepitant) | 7,050 | $0 | $5 |
| Immune globulin infusion (Octagam) | 6,080 | $33 | $233 |
| Denosumab injection (Prolia/Xgeva) | 5,880 | $18 | $65 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 5,310 | $23 | $155 |
| Dexamethasone injection (steroid) | 4,378 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,820 | $22 | $181 |
| Injection, bortezomib, 0.1 mg | 2,065 | $4 | $116 |
| Injection, bevacizumab, 10 mg | 1,770 | $56 | $196 |
| Injection, carboplatin, 50 mg | 1,015 | $2 | $300 |
| Blood draw (venipuncture) | 969 | $8 | $20 |
| Complete blood count (CBC) with differential | 897 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 780 | $1 | $114 |
| Comprehensive metabolic blood panel | 755 | $10 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 685 | $24 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 641 | $106 | $707 |
| Injection of additional new drug or substance into vein | 613 | $12 | $108 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 600 | $83 | $1,348 |
| Injection, potassium chloride, per 2 meq | 590 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 570 | $0 | $24 |
| Injection, fluorouracil, 500 mg | 557 | $2 | $13 |
| Injection, leucovorin calcium, per 50 mg | 486 | $3 | $25 |
| Office visit, established patient (30-39 min) | 425 | $95 | $368 |
| Injection, magnesium sulfate, per 500 mg | 360 | $1 | $6 |
| Ferritin level test (iron stores) | 357 | $13 | $60 |
| Iron level test | 335 | $6 | $27 |
| Iron binding capacity test | 335 | $9 | $35 |
| Infusion, normal saline solution , 1000 cc | 325 | $2 | $19 |
| Lactate dehydrogenase (enzyme) level | 311 | $6 | $31 |
| Administration of chemotherapy into vein, each additional hour | 306 | $23 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 291 | $53 | $344 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 290 | $20 | $128 |
| Injection, cisplatin, powder or solution, 10 mg | 287 | $2 | $94 |
| Carcinoembryonic antigen (cea) protein level | 270 | $19 | $99 |
| Injection, zoledronic acid, 1 mg | 253 | $7 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 239 | $16 | $100 |
| Injection, diphenhydramine hcl, up to 50 mg | 237 | $1 | $7 |
| Infusion into a vein for hydration, each additional hour | 218 | $10 | $75 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 207 | $51 | $313 |
| Drug injection, under skin or into muscle | 190 | $11 | $96 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 177 | $3 | $373 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 165 | $340 | $1,722 |
| Red blood count, automated test | 163 | $4 | $23 |
| Anti-nausea injection (ondansetron/Zofran) | 152 | $0 | $6 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 137 | $59 | $211 |
| Infusion into a vein for hydration, 31-60 minutes | 135 | $27 | $256 |
| Uric acid level test | 133 | $4 | $25 |
| Immunoglobulin level test | 127 | $9 | $56 |
| Measurement of immunoglobulin light chains | 118 | $17 | $60 |
| Hospital follow-up visit, high complexity | 117 | $94 | $357 |
| Unclassified drugs | 116 | $1 | $8 |
| Beta-2 microglobulin (protein) level | 104 | $16 | $96 |
| Thyroid stimulating hormone (TSH) test | 93 | $16 | $80 |
| Office visit, established patient, complex (40-54 min) | 78 | $140 | $496 |
| Injection of drug or substance into vein | 76 | $29 | $247 |
| Administration of additional new drug or substance into vein using push technique | 67 | $46 | $289 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 60 | $1 | $19 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 53 | $136 | $500 |
| Application of on-body injector for under skin injection | 50 | $15 | $96 |
| Reticulated (young) platelet measurement | 45 | $35 | $143 |
| Microscopic examination for white blood cells with manual cell count | 43 | $4 | $22 |
| Complete blood count (CBC), automated | 43 | $6 | $34 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 40 | $134 | $3,675 |
| Vitamin B-12 level test | 36 | $15 | $76 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $16 | $94 |
| Office visit, established patient (20-29 min) | 35 | $62 | $250 |
| Folic acid level test | 33 | $14 | $73 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 32 | $27 | $145 |
| Initial hospital admission, high complexity | 32 | $135 | $694 |
| Urinalysis with microscopic exam | 31 | $3 | $28 |
| Protein measurement, serum | 27 | $11 | $99 |
| Immunologic analysis technique on serum | 27 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 27 | $22 | $160 |
| Drawing of blood for a medical problem | 23 | $70 | $264 |
| New patient office visit, complex (60-74 min) | 23 | $159 | $709 |
| Vitamin D level test | 21 | $29 | $250 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 19 | $1,229 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 18 | $92 | $657 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
14.3% high complexity
81.4% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$304
Total received (2021-2024)
Avg $76/year across 4 years
Bottom 17% in TX for medical oncology
10
Companies
14
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$184 (60.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$120 (39.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$113
2023$31
2022$133
2021$27
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$76
E.R. Squibb & Sons, L.L.C.
$58
Novartis Pharmaceuticals Corporation
$44
Celgene Corporation
$36
Regeneron Healthcare Solutions, Inc.
$17
EMD Serono, Inc.
$16
Genentech USA, Inc.
$16
Seagen Inc.
$16
Puma Biotechnology, Inc.
$15
Gilead Sciences, Inc.
$12
Top 3 companies account for 58.3% of total payments
Associated products mentioned in payments ›
BAVENCIO · Fabhalta · LIBTAYO · OPDIVO · PADCEV · PROMACTA · Perjeta · Pomalyst · REBLOZYL
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (61%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $0 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
25
Per 100K population
1.9
County median income
$97,169
Nearest hospital
AUSTIN OAKS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Tebcherany is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Tebcherany experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Tebcherany performed 26,200 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tebcherany receive payments from pharmaceutical companies?
Yes. Dr. Tebcherany received a total of $304 from 10 companies across 14 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tebcherany's costs compare to other medical oncologys in Austin?
Dr. Tebcherany's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tebcherany) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Austin
Browse medical oncologys in Austin ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology